High-dose carfilzomib achieves superior anti-tumor activity over low-dose and recaptures response in relapsed/refractory multiple myeloma resistant to low-dose carfilzomib by co-inhibiting the β2 and β1 subunits of the proteasome complex

Optimal carfilzomib dosing is a matter of debate. We analyzed the inhibition profiles of proteolytic proteasome subunits β5, β2 and β1 after low-dose (20/27 mg/m(2)) versus high-dose (≥36 mg/m(2)) carfilzomib in 103 pairs of peripheral blood mononuclear cells from patients with relapsed/refractory (...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Xiang, Besse, Andrej, Peter, Jessica, Steinhardt, Maximilian Johannes, Vogt, Cornelia, Nerreter, Silvia, Teufel, Eva, Stanojkovska, Emilia, Xiao, Xianghui, Hornburger, Hannah, Haertle, Larissa, Mendez-Lopez, Max, Munawar, Umair, Riedel, Angela, Han, Seungbin, Maurits, Elmer, Overkleeft, Herman S., Florea, Bogdan, Einsele, Hermann, Kortüm, K. Martin, Driessen, Christoph, Besse, Lenka, Rasche, Leo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2023
Materias:
Article - Plasma Cell Disorders
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230416/
https://www.ncbi.nlm.nih.gov/pubmed/36727403
http://dx.doi.org/10.3324/haematol.2022.282225

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230416/
https://www.ncbi.nlm.nih.gov/pubmed/36727403
http://dx.doi.org/10.3324/haematol.2022.282225

Ejemplares similares